Next-Generation Innovations

G3 Genomics was formed as a permanent capital vehicle for opportunistic consolidation and growth in molecular diagnostics and genomics. We acquire established platforms, operate them with operational excellence, and incubate emerging technologies—from early-stage ventures to FDA-cleared platforms.

Our Mission: Build a diversified portfolio of diagnostic and genomics assets through disciplined acquisition, active operations, and strategic incubation.

What We Do:

• Acquire and operate diagnostic and genomic testing platforms
• Develop diagnostic products, reagents, and enabling technologies
• Incubate emerging diagnostic and genomic platforms from concept through commercialization

Our Approach: Permanent capital without fund-driven exit timelines enables multi-year infrastructure investments, opportunistic M&A, technology development cycles, and strategic consolidation without liquidity pressure. We hold assets to generate cash flow and compound value over 10-25+ years.​

Our Values: Scientific Integrity | Operational Discipline | Long-Term Stewardship | Transparency

The molecular diagnostics and genomics market is experiencing sustained growth driven by precision medicine adoption, NGS expansion, and biomarker-driven testing integration. Growth accelerates across oncology screening, infectious disease, and companion diagnostics as reimbursement shifts toward value-based care.​

The market remains fragmented, creating consolidation opportunities for well-capitalized platforms that achieve back-office centralization, laboratory automation, and vendor economies of scale. Rising regulatory complexity and reimbursement constraints are accelerating consolidation among independent laboratories and diagnostic providers.

G3 executes a dual strategy: acquiring and consolidating established genomic and diagnostic platforms while incubating early-stage technologies.​

Acquisition Profile:
Established operational companies and assets with proven customer relationships, validated assays, defensible IP, and clear paths to margin improvement in high-growth markets—precision medicine, oncology, infectious disease, genomic screening.

Incubation Focus:
Early-stage diagnostics and genomics technologies, novel biomarker platforms, and next-generation molecular assays with scientific validation and regulatory potential.

Value Creation:

• Consolidation efficiencies: back-office centralization, automation investment, service line expansion
• Platform integration: EHR/EMR connectivity, data analytics, shared compliance and quality infrastructure
• Incubation support: development capital, regulatory expertise, access to G3's laboratory network for validation and scale-up, commercial infrastructure (sales, reimbursement)

Each portfolio company maintains operational autonomy and entrepreneurial culture while accessing shared platform capabilities.